List view / Grid view
Drug delivery refers to approaches for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect.
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
In this article, Drug Target Review’s Izzy Wood reviews some of the latest Alzheimer's disease research, highlighting the progress that has been made toward new, more unique therapeutic strategies against Alzheimer’s.
The researchers explored the possibility of using the probiotic bacteria Lactobacillus reuteri as a novel oral drug delivery platform to treat rheumatoid arthritis in an animal model.
The researchers found that the protein Grb10 promotes leptin activity in the brain, opening the possibility of developing Grb10-based new approaches to treat obesity.
US scientists have developed a potential medication for the genetic cause of ALS and dementia, that eliminates the mutated segments of RNA.
Biovac signs deal with IVI to develop and manufacture oral cholera vaccine (OCV) for African and global markets.
Japanese scientists underwent a study exploring trigeminal nerves and how the intranasal administration of the novel glucagon-like peptide-2 can produce antidepressant effects in mice.
US researchers have uncovered the uncapped potential that gut-friendly bacteria has for improving treatments of inflammatory bowel disease (IBD).
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
Researchers show how monkeypox mutations cause virus to replicate, spread faster.
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
The best protection from COVID-19 will come from intranasally-delivered vaccines, due to the effectiveness of mucosal IgA antibodies, say researchers from the University at Buffalo.
A newly developed AAV has shown promise at delivering gene therapies to the brain in mice and non-human primates.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
